Bio/Pharma Business

Pharmapack Experts Predict Increased Packaging Consolidations in 2023

January 31, 2023

Pharmapack Europe experts expect smaller and medium European packaging companies to grow or be acquired.

AstraZeneca and ThermoFisher to Collaborate on Companion Diagnostic Test

January 31, 2023

AstraZeneca and Thermo Fisher will collaborate to develop a solid tissue and blood-based companion diagnostic test for osimertinib.

Scientific Laboratory Supplies Acquires C&M Scientific

January 31, 2023

Scientific Laboratory Supplies’ acquisition of C&M will bolster the company’s scientific calibration, maintenance, and validation offerings.

Amgen, Illumina, and Nashville Biosciences Announce Genome Sequencing Agreement

January 26, 2023

deCODE genetics, a subsidiary of Amgen, will whole-genome sequence 35,000 African-American samples provided by Illumina and Nashville Biosciences.

USPTO Issues Notice of Allowance for Zika Vaccine Patent

January 26, 2023

The United States Patent and Trademark Office issued a Notice of Allowance for Zika vaccine patent to GeoVax.

Takeda Strikes $1.13 Billion Deal for Hutchmed Colorectal Cancer Treatment

January 23, 2023

Takeda will pay approximately $400 million upfront for the exclusive worldwide rights to Hutchmed’s fruquintinib, a tyrosine kinase inhibitor, outside of China.

Pfizer and Gero Form Collaboration to Discover Potential Targets for Fibrotic Diseases

January 18, 2023

Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.

AbbVie and Anima Biotech Partner on Discovery and Development of mRNA Biology Modulators

January 18, 2023

The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.

AstraZeneca Inks $1.8 Billion Acquisition for CinCor Pharma

January 11, 2023

The definitive agreement will give AstraZeneca global rights to CinCor’s portfolio of cardiorenal disease treatments.

Chiesi Acquires Rare Diseases Company in $1.47 Billion Deal

January 11, 2023

Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.